This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Michopoulos S, Petraki K, Matsouka C, Kastritis E, Chrysanthopoulou H, Dimopoulos MA . Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract. J Clin Oncol 2008; 26: 1555–1557.
Ghielmini M, Zucca E . How I treat mantle cell lymphoma. Blood 2009; 114: 1469–1476.
Meral M, Demirpence M, Gonen C, Akarsu M, Kayahan H, Demirkan F et al. Diffuse gastrointestinal involvement of mantle cell lymphoma. Turk J Gastroenterol 2008; 19: 117–120.
Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003; 97: 586–591.
Iwamuro M, Okada H, Kawahara Y, Shinagawa K, Morito T, Yoshino T et al. Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement. World J Gastroenterol 2010; 16: 4661–4669.
Dreyling M, Hiddemann W . Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009; 1: 542–551.
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463.
Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K et al. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 2009; 100: 158–164.
Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 5213–5218.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Han, E., Yang, SA., Sohn, HS. et al. Successful treatment with tandem consolidation using 90yttrium-ibritumomab tiuxetan (Zevalin) and high-dose therapy with autologous PBSCT in a patient with relapsed mantle cell lymphoma presenting as multiple lymphomatous polyposis. Bone Marrow Transplant 47, 877–879 (2012). https://doi.org/10.1038/bmt.2011.193
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2011.193